• These were the worst performing ASX 200 shares last week

    The S&P/ASX 200 Index (ASX: XJO) gave back its midweek gains on Friday and dropped notably lower. As a result, the index recorded a weekly decline of 0.2% to 6024 points.

    While a good number of shares dropped lower last week, some stood out with particularly sharp declines. Here’s why these were the worst performing ASX 200 shares over the period:

    The Alumina Limited (ASX: AWC) share price was the worst performer on the index last week with a 7.2% decline. Investors appear to have been taking profit after the alumina and bauxite producer’s shares surged higher a week earlier following its quarterly update. One broker that believes this has created a buying opportunity is Morgan Stanley. Last week it retained its overweight rating and price target of $2.00.

    The Cooper Energy Ltd (ASX: COE) share price wasn’t far behind with a 7.1% decline. This appears to have been driven by a broker note out of Macquarie. According to the note, the broker downgraded the gas producer’s shares to a neutral rating and cut the price target on them to 44 cents. Macquarie made the move after Cooper Energy’s guidance for FY 2021 disappointed. The broker doesn’t expect its earnings to be positive until FY 2022 now.

    The Western Areas Ltd (ASX: WSA) share price was out of form and dropped 6.6% lower last week. The majority of this decline came on Friday when the nickel producer released its fourth quarter and full year production update. Western Areas produced 5,114 nickel tonnes in concentrate for the quarter, bringing its full year production to 20,926 tonnes. This was just a touch short of its guidance. Operating cashflow came in at $22.9 million, leaving Western Areas with cash at the bank of $144.8 million and no debt.

    The TPG Telecom Ltd (ASX: TPG) share price was a poor performer and fell 6.1% last week. The catalyst for this appears to be a broker note out of Credit Suisse. It reinitiated coverage on the newly merged telco with an underperform rating and $7.35 price target. It is expecting a step down in the company’s operating income in FY 2020 because of lower sales in mobile services and roaming revenues.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post These were the worst performing ASX 200 shares last week appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3jGbab9

  • 5 simple steps to financial independence

    chalkboard with financial freedom goal

    Financial independence. If you ask 100 different people you’ll probably get 100 different answers as to what it actually is.

    To me, it’s the ability to do what I like, when I like. If you love your job, that means continuing to work but with a strong safety net behind you.

    The idea sounds great, but to many people financial independence can seem like a pipe dream.

    Here are 5 simple steps to help anyone start working towards a stress-free retirement today.

    1. Slash your expenses

    This is a biggie. If you want to achieve financial freedom, having a good hard look at your current expenses is key.

    You don’t have to go to austerity, eating beans and rice and listening to the radio.

    However, you should look at what you’re spending and where. Have a think about whether you’re really getting good value from that Netflix subscription or lunches out everyday.

    2. Pay down “bad” debts

    Bad debts can be a financial independence killer. Credit card and other personal debts can quickly spiral out of control.

    If you want to achieve financial freedom, paying down those high-interest debt obligations is an important step.

    Look at balance transfers to low or no-interest cards and direct any spare cash towards paying down those bad debts.

    3. Make a budget

    Once your expenses and bad debts are under control, it’s time to make a budget.

    Unless you’re very disciplined, it’s hard to achieve financial independence without some sort of budget. It’s a little bit like trying to drive to an unknown destination without a map.

    I like to sit down and make a budget of income, expenses and your personal “profit” each year. This will let you plot out how much of your income you’ll have left for investments.

    4. Save a consistent portion of your income

    It’s easy to splurge when you first see that income hit your bank account. Achieving financial independence doesn’t require magic, but it does require discipline.

    Rather than spending that money, make sure that you save it. If you can consistently save a good portion of your paycheck, you’ll be well on your way to financial freedom.

    5. Invest, invest, invest!

    Now that you’ve got your personal finances sorted, you can start to invest in some ASX shares!

    There are endless opportunities for investing and generating returns for the future. There are hot tech shares like Afterpay Ltd (ASX: APT) or dividend shares like Commonwealth Bank of Australia (ASX: CBA).

    If you’re just starting out, a diversified exchange-traded fund like Vanguard Australian Shares Index ETF (ASX: VAS) could be of interest.

    Whatever you choose to invest in, make sure you stay disciplined and invest for the long-term.

    To turbocharge your financial independence dreams, re-invest any dividends for strong compounding returns.

    Foolish takeaway

    This is just a quick guide to help investors make their financial independence dreams a reality.

    Increasing income can be challenging, particularly given the current economic landscape, but by slashing expenses and making a budget you’ll already be making positive steps in the right direction!

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor Ken Hall owns shares of Vanguard Australian Shares Index. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 5 simple steps to financial independence appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2BrIGAH

  • The CEO of the largest marijuana company says a blue wave could trigger legalization ‘very quickly’

    The CEO of the largest marijuana company says a blue wave could trigger legalization ‘very quickly’Marijuana company Curaleaf is expanding its footprint ahead of a growing chance of federal legalization.

    from Yahoo Finance https://ift.tt/30O6uY8

  • Results: Philip Morris International Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

    Results: Philip Morris International Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesThe quarterly results for Philip Morris International Inc. (NYSE:PM) were released last week, making it a good time to…

    from Yahoo Finance https://ift.tt/3fWUD0g

  • Casino Stock Analyst Says Things Are Going From Bad To Worse In Vegas

    Casino Stock Analyst Says Things Are Going From Bad To Worse In VegasThe initial reopening of the Las Vegas Strip went relatively well for casino operators in early June, but abysmal room rates and a second wave of the COVID-19 outbreak seems to have eliminated hope that the Vegas recovery will continue any time soon.Las Vegas Sands Corp.(NYSE: LVS) management told investors this week that Vegas is suffering "a world of hurt," and the U.S. gaming hub has a long way to go in recovering from its shutdown, according to BofA Securities.The Numbers: Pricing of Las Vegas Strip hotel room rates for the month of August is now down 40% from a year ago. Pricing conditions on the Strip have worsened since June 12 when August rates were down just 31%. September prices are also down 37% year-over-year, suggesting little improvement heading into the fall.Vegas strip operators Las Vegas Sands, MGM Resorts International (NYSE: MGM), Wynn Resorts, Limited (NASDAQ: WYNN) and Caesars Entertainment Corporation (NYSE: CZR) are taking a hit from the plummeting room rates, BofA analyst Shaun Kelley said in a note.Las Vegas Sands recently closed the Palazzo back up for weekday reservations after midweek occupancy levels dropped to 25% or lower."We see little reason to think these operating challenges are exclusive to LVS and we have seen recent furloughs from WYNN in addition to layoffs at the Tropicana and Circus Circus," Kelley said Friday.Bleak Outlook: BofA estimates Las Vegas Sands will take the smallest hit on room rates in August, down 13% compared to a year ago. Kelley said Wynn will take the largest hit, with room rates down 52%.Las Vegas Sands management said this week there is no evidence investors should expect the city's group and convention business to return anytime soon.KAYAK flight search data for Las Vegas is reportedly down 68% from a year ago. Clark County, Nevada reported more than 1,000 new COVID-19 cases on Thursday for the fifth day in the past week.Benzinga's Take: The two biggest questions for Vegas casino stock operators at this point is will reopened casinos stay open and how long will it take for travelers to return?For long-term investors looking to play the recovery, Bank of America has the following ratings and price targets for major Las Vegas casino operators: * Las Vegas Sands, Buy rating and $61 target. * Wynn, Buy rating and $95 target. * MGM Resorts, Underperform rating and $15 target.Related Links:Analyst: End Of Quarantine Restrictions 'Very Positive For Our Macau Stocks'Analyst: 'Trends Are Encouraging' For US Regional CasinosSee more from Benzinga * What Are EV Regulatory Credits And Why Is Tesla Selling So Many Of Them? * This Day In Market History: The Liquidation Of Corporate Fraud ZZZZ Best * Tesla's Valuation Still 'Appears Overcharged' Following Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2BqSCdI

  • These were the best performing ASX 200 shares last week

    best shares

    A poor finish to the week led to the S&P/ASX 200 Index (ASX: XJO) posting a small weekly decline. The benchmark index fell 0.2% to end it at 6024 points.

    Not all shares tumbled lower with the market last week, though. Here’s why these ASX 200 shares were the best performers on the index over the period:

    The Resolute Mining Limited (ASX: RSG) share price was the best performer on the ASX 200 last week with a 17.8% gain. Investors were buying the gold miner’s shares after the release of its second quarter update. During the quarter, Resolute achieved gold production of 107,183 ounces at an all-in sustaining cost (AISC) of US$1,033 an ounce. This means Resolute is on course to achieve its FY 2020 guidance of 430,000 ounces at an AISC of US$980 an ounce. The latter was notably lower than its average realised price of US$1,446 an ounce for the period. Fellow gold miner Silver Lake Resources Limited (ASX: SLR) was also a strong performer last week with an 11.6% gain. This follows the release of its quarterly update.

    The AP Eagers Ltd (ASX: APE) share price was on form last week and recorded a strong 16.8% gain. The catalyst for this gain appears to have been a broker note out of UBS. Its analysts have initiated coverage on the auto retailer with a buy rating and $7.90 price target. Although it acknowledges that trading conditions are tough, it believes AP Eagers is well-placed to deliver structural improvements in its profitability over the medium term.

    The Orocobre Limited (ASX: ORE) share price wasn’t far behind with a 13.2% gain. This was despite there being no news out of the lithium miner last week. However, investors have been buying Orocobre’s shares since its update in late June. So much so, the Orocobre share price is now up over 26% since this time last month.

    The QBE Insurance Group Ltd (ASX: QBE) share price was a solid performer and rose 11% last week. Investors were buying the insurance giant’s shares after it revealed its expectations for the first half of FY 2020. QBE expects to report a first half combined operating ratio of around 104%, which reflects COVID-19 impacts of around $335 million, adverse catastrophe experience of around $60 million, and adverse prior accident year claims development of around $120 million. One broker that was pleased with its progress was Morgan Stanley. It has retained its overweight rating and lifted its price target to $12.50.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post These were the best performing ASX 200 shares last week appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2WT965Y

  • Novavax’s 3,500% Surge on a Covid-19 Vaccine Faces First Test

    Novavax’s 3,500% Surge on a Covid-19 Vaccine Faces First Test(Bloomberg) — Novavax Inc.’s Covid-19 vaccine results are expected imminently and scientists will be scanning the data to gauge the shot’s promise. At the same time, day traders — who’ve snapped up shares since March — will be looking for the more than $7 billion surge in value to hold.Vaccine candidates presented so far have detailed initial patient antibody and T-cell responses and compared them with levels seen in patients who have recovered from the virus. Investors will be looking for those initial immune-system responses when Novavax reveals its data, likely sometime next week.Novavax is on its way to becoming a household name similar to Moderna Inc., another vaccine developer that has rallied since March but has yet to have a product reach the market. Recent $1.6 billion funding from the U.S. government has bolstered Novavax’s credibility despite some concern over its use of industry ties to get that backing.The need for a vaccine is clear, with Covid-19 cases in the U.S. reaching beyond 4 million and the virus on the rise across the Sunbelt. There are roughly 25 vaccines in human testing with more than 140 others in earlier stages of development, according to the World Health Organization.The market has responded positively to some of the first results in people from Moderna, as well as Pfizer Inc. and BioNTech SE’s messenger RNA vaccines. AstraZeneca Plc’s experimental shot with the University of Oxford was compared less favorably by some on Wall Street. Biotechs that didn’t provide sufficient detail have given back some of their share gains.Insect CellsNovavax’s vaccine — NVX-CoV2373 — uses insect cells to grow key proteins and the company has said it could be easier to mass produce than some rival shots. NVX-CoV2373 is being tested in a two dose regimen, with some patients getting a formulation enhanced with the company’s proprietary plant-based nanoparticle technology meant to further stimulate an immune response.Results so far have measured these immune responses at different time points and using different measures, making them difficult to compare.“It’s an imperfect situation,” said Steven Seedhouse, an analyst at Raymond James in a phone call. “There’s data out there, to the extent you can you do your best to interpret it.”Early antibody results from BioNTech-partnered Pfizer have looked the most promising so far, said Seedhouse who has a doctorate in molecular pharmacology. “We don’t know what’s going to confer immunity and we certainly don’t know what’s going to confer durable immunity.”JPMorgan Chase analyst Eric Joseph was also positive on Pfizer’s vaccine. Its results that generated virus-neutralizing antibodies as much as threefold higher than those found in patients who had recovered from Covid-19 create “a challenging setup” for Novavax.Safety, of course, is paramount for vaccines given to healthy people, and results in the leading candidates so far haven’t raised any major red flags.Tolerability CautionHowever, Joseph, who is neutral on Novavax, cautioned on potential tolerability issues. Its Covid-19 vaccine uses the same technology that’s in its still experimental flu shot, which has shown more adverse events after treatment than a comparative flu shot, Joseph wrote in a note to clients.Still for bears betting against the company, the stakes are high. Short sellers have lost just over $1 billion this year, according to Ihor Dusaniwsky, managing director for predictive analytics at S3 Partners. With about $1.3 billion of shares sold short, the stock is a prime squeeze candidate, according to his analysis.Vaccine stocks, including Novavax, show options investors are positioning for an imbalanced risk that shares will post outsize gains, according to Goldman Sachs analysts led by Terence Flynn. Call options on Covid-19 stocks like Novavax are “unusually expensive” compared with puts, they said.Options data imply Gaithersburg, Maryland-based Novavax could move an additional 14% through July 31. Investors trying to get ahead of stock moves should also watch shares of a Novavax partner, Emergent BioSolutions Inc., which provides manufacturing and development services out of a handful of sites in Maryland.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/3jC0z11